Aurobindo Pharma
Aurobindo Pharma Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
From Aurobindo Pharma's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Consolidated revenues increased by 16% YoY to Rs. 9,150 crores, driven by broad-based business performance.
- Formulation business grew 17% YoY, contributing ~89% of revenues.
- U.S. revenues up 8.1% YoY with 10 new product launches and 9 ANDA filings in the quarter.
- European business expects double-digit growth in FY27 with continued new launches.
- Growth markets increased 38% YoY, with expansion in countries like Indonesia, China, and Canada.
- FY27 guidance: double-digit revenue growth, EBITDA margins above 21%, EBITDA exceeding Rs. 8,000 crores.
- Biosimilar and biological CMO businesses are long-term growth drivers.
- TheraNym CDMO revenues expected to start from 2028 (~$150-$200 million by 2032) with 35-50% EBITDA margins.
- China facility production doubled, aiming to exceed 2 billion tablets by mid-next year.
- Strong pipeline execution with multiple near-term product filings, especially in complex respiratory and controlled substance portfolios.
Profitability & Margins
See what Aurobindo Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
- The Lannett acquisition has provided substantial manufacturing capacity and strategic benefits with minimal additional CAPEX needed in the short term.
- Aurobindo has scope for expansion at existing facilities, including Lannett and Aurolife units, and has a reserve facility that can be quickly brought online if required.
- The recent acquisition of A1 Biochem (a CRO) complements existing API capabilities, aiming to develop an integrated CRDMO, accelerating growth by 3-5 times over 3-5 years versus greenfield investment taking 5 years.
- Focus on backward integration and investment in complex generics, specialty pharmaceuticals, injectables, biologics, and CDMO services to build durable competitive advantages and improve returns.
- Overall, investments made over the last decade are transitioning from the investment phase to monetization, improving margins, cash flows, and returns on capital.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aurobindo Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Aurobindo Pharma — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹8.9K Cr, net profit ₹921 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Aurobindo Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Aurobindo Pharma Q1 FY27 results?
Consolidated revenues increased by 16% YoY to Rs. Aurobindo Pharma expects double-digit revenue growth for FY27, driven by broad-based performance across key markets including the U.S., Europe, and growth markets.
What is Aurobindo Pharma share price analysis?
Aurobindo Pharma currently shows a below-average growth signal. The stock trades at a P/E of 24.9 with a market cap of ₹94,165 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aurobindo Pharma planning capital expenditure?
Net CapEx for the quarter was $78 million, mainly focused on TheraNym Biologics.
Keep Aurobindo Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.